Trevi Therapeutics Inc Investor Relations Material
Latest events
Q3 2023
Trevi Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Trevi Therapeutics, Inc a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
Latest articles
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
The Story of Jensen Huang and Nvidia
When looking at NVIDIA’s Jensen Huang today, it is easy to stereotype him as your archetypical big tech CEO. He doesn’t wear suits like a Wall Street Chairman, instead opting to wear his now-iconic leather jackets and casual polo shirts.
6 Dec 2023
Neglect of Probability: A Hidden Risk in Decision Making
The concept of "probability" should take center stage in our decision-making processes.
4 Dec 2023
Ticker symbol
TRVI
Country
🇺🇸 United States